Medicortex Finland Oyj

What Medicortex Finland Oyj does

Medicortex Finland Oyj is a privately held Finnish biotech founded in June 2014 in Turku by neurobiologist Dr. Adrian Harel, headquartered in the PharmaCity/Werstas bioincubator in Turku Science Park. The company is developing a rapid, point-of-care diagnostic test kit for Traumatic Brain Injury (TBI) and concussion, based on proprietary glycan-based biomarkers detected in non-invasive samples such as urine or saliva using lectin-binding chemistry. Three clinical studies have been completed in Finnish hospitals (Turku University Hospital/Tyks, Satakunta Central Hospital, Vaasa Central Hospital and Satasairaala in Pori), validating the biomarker in adult and pediatric populations across 24, 69 and 58 subjects respectively.

The core product under development is a single-use handheld test designed to deliver a yes/no TBI result without electricity, software, maintenance or specialist interpretation, intended for use in emergency departments, military field settings, sports first-aid kits, nursing homes, schools, insurance workflows and over-the-counter pharmacy sales. In parallel, Medicortex runs a drug development program for neuroprotective novel chemical entities designed to cross the blood-brain barrier. The IP portfolio covers granted patents in the EU, US, Canada, Israel, Australia, China, Finland and Germany, spanning biomarker methods, diagnostic devices and compounds, and the Medicortex trademark was approved by EUIPO in June 2026.

Revenue generation has not commenced; the company is pre-commercial and funded primarily through non-dilutive grants (over $3.4 million cumulatively from the US Department of Defense, plus €411,000 from Business Finland) and a €500,000 pre-IPO equity round in 2021. Distribution is planned across multiple channels: direct enterprise sales to hospitals, defence customers and sports organisations, OTC pharmacy retail for consumers, and a strategic partnership with a large diagnostics company for co-development and commercialisation. The company is currently undergoing a reverse takeover with Swedish public company Nosium AB (publ) and received NGM Growth Market conditional listing approval in June 2026, with the listed entity to be renamed Medicortex International AB (publ).

Name

Medicortex Finland Oyj

Legal name

Medicortex Finland Oyj

Website

https://medicortex.fi

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Medicortex Finland Oyj is a Turku-based biotech developing a rapid, non-invasive point-of-care diagnostic test for Traumatic Brain Injury using proprietary glycan biomarkers detected in urine or saliva. It targets hospitals, emergency services, military, sports organisations and OTC pharmacy consumers, and is preparing for public listing via reverse takeover.

Ownership category

akta.pro rank

Product category

Point-of-Care Traumatic Brain Injury Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industry

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Traumatic brain injury diagnostics
• Biomarker-based diagnostic tests
• Point-of-care diagnostics
• Non-invasive diagnostic kits
• Neuroprotective drug development

Headquarters

HQ city

Turku

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. TBI Diagnostic Test Kit Sales: Revenue from sale of handheld rapid diagnostic kits for detecting Traumatic Brain Injury from non-invasive samples (urine or saliva). The product is under development with prototype phase underway.
2. Over-the-Counter Consumer Test Sales: Direct-to-consumer sales of test kits through pharmacies. Planned retail channel for private individuals to purchase without prescription.
3. Pharmaceutical Partnership / Licensing: Long-term revenue model through partnerships with large pharmaceutical or diagnostics companies for co-development and commercialization. Also revenue from pharma companies using the test as endpoint measure in clinical trials.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Medicortex Finland Oyj is developing a rapid, non-invasive, point-of-care diagnostic test kit for detecting Traumatic Brain Injury (TBI) and concussion using proprietary glycan biomarkers measured from urine or saliva samples. The product is designed to deliver a simple yes/no result within minutes without electricity, software, or specialized staff, functioning like a pregnancy test. The company has validated the biomarker across three completed clinical studies (24, 69, and 58 subjects, including pediatric populations) and operates a parallel drug development program for neuroprotective compounds targeting post-TBI treatment.

Product overview

Medicortex Finland Oyj is developing a biomarker-based diagnostic test kit as its primary product offering. The core product is a rapid, non-invasive TBI diagnostic test that detects proprietary biomarkers from urine or saliva samples. The company has completed three clinical studies validating the biomarker in adults and children. In parallel, the company operates a drug development program as a future product initiative, focused on developing neuroprotective compounds for treating brain injury after the diagnostic product reaches market.

Differentiator

Problem solved

Functional benefit

Products and services

• TBI Diagnostic Test Kit A rapid, non-invasive, point-of-care diagnostic test kit for detecting Traumatic Brain Injury (TBI) and concussion through proprietary glycan biomarkers measured from urine or saliva samples. Designed to deliver a simple yes/no result within minutes without requiring electricity, software, maintenance, or specialized staff, functioning similarly to a pregnancy test. Targeted at hospitals, emergency departments, military, sports organizations, insurance companies, and over-the-counter pharmacy consumers.
• Neuroprotective Drug Development Program A pipeline drug development program creating multivalent neuroprotective New Chemical Entities (NCEs) with lipophilic properties designed to cross the blood-brain barrier. The compounds combine free metal ion binding, anti-oxidation, and anti-inflammatory functions to halt the post-TBI biochemical cascade. Protected by multiple granted patents.

Quantifiable outcome

• TBI POC diagnostics market exceeds €2 billion annually (also cited as €3.3 billion in CEO letter)
• +2 more outcomes

Named customers4 records

Segments9 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• Nosium AB (publ)flagshipStrategic or Co-development Partner · 25 June 2025Medicortex signed a Letter of Intent with Swedish public company Nosium AB for a reverse acquisition (RTO). The transaction will result in Medicortex becoming part of Nosium and listing on Nordic Growth Market (NGM). Majority shareholders (52.9%) signed a Share Purchase Agreement (SPA); over 80% of shares committed to the transaction. NGM conditionally approved the listing after RTO completion in June 2026.
• Grant Thornton Advico Finland OycoreImplementation/ SI/ Consulting Partner · 1 January 2023External auditor of the company. Riku Vuorinen from Grant Thornton serves as the company's auditor. Located at Maariankatu 6 A 66, Turku.
• Satasairaala (Pori, Finland)coreStrategic or Co-development Partner · 1 January 2021Satasairaala hospital in Pori conducted sample collection for the third clinical study on pediatric TBI. A total of 58 children and adolescents aged 0-17 were recruited, including 28 with suspected mild TBI and 30 healthy controls.
• Helsingin yliopisto (University of Helsinki) — Pää pelissä projectminorStrategic or Co-development Partner · 1 January 2020Collaboration with the University of Helsinki's Pää pelissä project and Tampereen Urheilulääkäriasema's Terve Urheilija program to produce Finnish-language educational animation on concussions in sports.
• Tyks (Turku University Hospital)coreStrategic or Co-development Partner · 1 January 2017Clinical collaboration for biomarker validation studies. Tyks served as the primary hospital for the first clinical study (2016-2017) and one of the hospitals for the second clinical study (2017-2019) involving 69 subjects.
• Satakunnan keskussairaala (Satakunta Central Hospital)coreStrategic or Co-development Partner · 1 January 2017Collaborating hospital in the second clinical study alongside Tyks and Vaasa Central Hospital. Contributed to sample collection from 69 subjects including TBI patients, orthopedic injury patients, and healthy controls.
• Vaasan keskussairaala (Vaasa Central Hospital)coreStrategic or Co-development Partner · 1 January 2017Collaborating hospital in the second clinical study alongside Tyks and Satakunta Central Hospital. Part of the multi-center clinical study validating the biomarker in 69 subjects.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Bio-Rad Laboratories: Established diagnostics and life-science research company with immunoassay and clinical chemistry platforms relevant to TBI biomarker workflows; comparable as a broad diagnostics manufacturer whose product portfolio overlaps with Medicortex's potential menu of CNS biomarker assays.
• Abbott Laboratories: Global diagnostics incumbent whose i-STAT Alinity TBI blood test (acquired from Banyan) directly competes in the TBI biomarker POC market; comparable because both companies target rapid hospital-based TBI rule-out and Abbott represents the dominant incumbent Medicortex would need to partner with or displace.
• Hologic: Diagnostics and women's health company with a significant molecular and immunoassay franchise; comparable as a broad diagnostics incumbent whose women's health screening channels and POC strategy offer a template for Medicortex's planned OTC and primary-care distribution.
• Siemens Healthineers: Global diagnostics and imaging incumbent whose Atellica and ADVIA Centaur immunoassay platforms compete in the hospital TBI workup pathway; comparable as a potential strategic acquirer/partner for Medicortex and as a benchmark for the scale of sales infrastructure required to penetrate hospitals globally.
• Roche Diagnostics: World's largest in-vitro diagnostics company with broad hospital POC and central-lab offerings; comparable as the type of large strategic partner Medicortex explicitly targets for commercialization and licensing, and whose cobas/Tina-quant immunoassay platforms exemplify the established competition in clinical biomarker testing.
• QuidelOrtho: Large diagnostics manufacturer with a broad POC and immunoassay portfolio; comparable because both companies serve the rapid-diagnostics segment and QuidelOrtho's experience scaling lateral-flow and immunoassay kits provides a benchmark for the manufacturing and distribution Medicortex will require.

Emerging players

• Quanterix: Developer of ultra-sensitive biomarker detection platforms (Simoa) used in neurology and TBI research; comparable to Medicortex as both companies commercialize novel biomarker assay technology for CNS indications, though Quanterix sells instruments/reagents to research labs rather than a disposable POC kit.
• BioDirection: Earlier-stage US company developing a rapid blood-based TBI biomarker test (Tbit) for concussion triage; comparable to Medicortex as a direct head-injury diagnostics peer targeting the same ED/sports/military use cases, though with a different sample matrix and biomarker approach.
• Abionic: Swiss POC diagnostics developer with a nanofluidic platform enabling rapid bedside biomarker tests; comparable to Medicortex as a small European diagnostics company commercializing novel POC biomarker technology with both clinical and emerging consumer/OTC channels.

Direct peers

• Banyan Biomarkers: Direct competitor in blood-based TBI biomarker diagnostics; developed the Brain Trauma Indicator that received FDA authorization and was later acquired by Abbott, making it the closest analog for Medicortex's biomarker-based TBI test (different sample matrix but same clinical use case).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/results?search_query=medicortex
• Facebookfacebook.com/medicortex
• LinkedInlinkedin.com/company/medicortexfinlandoyj
• Xx.com/AdrianHarel

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicortex Finland Oyj